Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2021 Q1- Text added to 2021 Q2
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. freshman Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. freshman Avg
|
New words:
arrant, AstraZeneca, biomarker, Biotechnologische, buy, cellular, characteristic, composition, CPI, DBH, description, diffuse, DLBCL, Inline, lung, lymphoma, marking, melanoma, metastatic, MSD, NSCLC, ourAnnual, parallel, pembrolizumab, PK, plc, randomized, rapid, respectivew, Side, subleasesthe, tern, thew, thisfacility, threeand, UKestablished, und, untreated, uptake, validation
Removed:
amortized, Distinguishing, oncology, solid, targeting
Valuein 2021 Q1 filing- Value in 2021 Q2 filing
Original filings
Filing view